PIK3CA and cancer: However, many of the studied PI3K/AKT/mTOR inhibitors exhibited only modest anticancer activities in patients and/or prohibitive toxicities, and only a small number of these agents have thus far been approved for clinical treatment of a small number of selected cancers [27,67].